Understanding how DUSP2 affects T cell responses to cancer immunotherapy
DUSP2 in Negative Regulation of Cytotoxic T Cell Responses to Immunotherapy
This study is looking at how a protein called DUSP2 affects the way a type of immune cell, known as CD8+ T cells, helps fight cancer during immunotherapy, with the goal of finding new ways to make these treatments work better for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11075119 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called DUSP2 in regulating the effectiveness of immunotherapy for cancer patients. It focuses on a specific type of immune cell, the CD8+ T cell, which is crucial for attacking tumors. By studying how DUSP2 influences these cells' ability to respond to treatment, the researchers aim to identify new therapeutic targets that could enhance the effectiveness of immunotherapy. The approach includes analyzing human T cells and using advanced techniques like single-cell RNA sequencing to gather detailed insights.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing immunotherapy who may benefit from enhanced T cell responses.
Not a fit: Patients who are not receiving immunotherapy or those with conditions unrelated to T cell function may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments for cancer patients, potentially increasing the number of patients who respond positively to these therapies.
How similar studies have performed: Previous research has shown promising results regarding the role of DUSP2 in T cell function, indicating that this area of investigation could lead to significant advancements in cancer treatment.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Dellacecca, Emilia R — Mayo Clinic Rochester
- Study coordinator: Dellacecca, Emilia R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.